Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
中
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Our Science
>
Our Science
>
Poster and Presentation
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Poster and Presentation
2020 ADA Poster
The Anti-diabetic Effect of Dorzagliatin in Chinese Patients with Type 2 Diabetes.
Read More
2020 ADA Poster
Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients Results of 24 Week Treatment in a Phase III Monotherapy Trial (SEED Study)
Read More
2019 ADA Poster
Dorzagliatin differentiates from early generation of glucokinase activators: an enzyme kinetics study.
Read More
2019 ADA Poster
Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care
Read More
2018 ADA Poster
Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator, Dorzagliatin (HMS5552) 12 Weeks Treatment in T2D Patients in China
Read More
2017 June
Clinical Proof of Concept (POC) of A Novel Dual-acting Glucokinase Activator (GKA) Achieved: HMS5552 improved glycemic control in T2DM Patients
Read More
<<
<
1
2
3
4
5
>
>>
上一页
下一页
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
Privacy Statement
Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our
privacy statement
.
Accept
x
大丰之声
足球外围平台
北京吉利学院
Sun-City-Entertainment-media@yunxiabc.com
皇冠体育博彩
Gambling-website-feedback@bhmingliang.com
Galaxy-Macau-Online-Casino-help@obliquido.com
安丘信息网
赌球网站
皇冠足球
澳门威尼斯人
潍坊赶集网
皇冠体育博彩
太阳城体育
XDACN|智能设备论坛
威廉希尔中文
地宝网搜索
Grand-Lisboa-hr@uv-uv.com
盐城网
Crown-Sports-sales@serimutiara.com
2014巴西世界杯_网易体育
广信担保
合锐赛尔
迅播影院
中影人艺考
有颜色
58同城铜陵分类信息网
武汉邮电科学研究院
广东工程职业技术学院
香江控股
RIMOWA中国官方商城
一起吧购物
站点地图